Message #23 From:
Stock News Bot Date: January 11, 2007 06:54:00 AM
NPHC News Nutra Pharma Announces Breakthrough Research in the Treatment of Viral Infections
BOCA RATON, Fla.--(BUSINESS WIRE)--Nutra Pharma Corp. (OTCBB:NPHC), a biotechnology company that is
developing drugs for HIV and Multiple Sclerosis, has today announced
that its contract researchers, Eno Research and Development, Inc.
(ERDI), recently completed their analysis of a series of microarray
studies with ReceptoPharm’s antiviral drug
candidates in healthy immune cells.
“The microarray studies indicate that the
exposure of healthy immune T-cells to our antiviral drugs activates the
primary immune mechanisms,” explained Dr. Paul
Reid, CEO of ReceptoPharm, Inc. “The
expression of one such immune trigger, interferon gamma, is
increased by as much as 20 times, acting as an effective antiviral
agent, but without the significant negative clinical side effects of
other interferon-based therapies. It has certainly helped explain the
broad antiviral activity observed with these types of agents. Based upon
this data, these products could conceivably be used to substitute for
the flu shot in winter or protect against other contagious viral
diseases when vaccines are not readily available,”
he added.
RPI-MN is the lead antiviral drug candidate of Nutra Pharma's holding,
ReceptoPharm, Inc. It is being studied for its potential in treating HIV
and other viral diseases.
“These findings could in fact revolutionize
the antiviral pharmaceutical industry,”
commented Rik J. Deitsch, Chairman and CEO of Nutra Pharma Corporation. “Providing
patients with a safe, beneficial and cost effective antiviral medicine
will allow millions of additional people to obtain treatments that were
once out of reach,” he concluded.
With the spread of bird flu and worldwide worries about a possible
influenza pandemic, antiviral medicines have recently received increased
media exposure. During the 2005-2006 flu season, healthcare providers
experienced a widespread shortage of the leading antiviral medicine,
Tamiflu by Roche (other-otc: RHHBY), which left millions of patients
without access to influenza prevention.
About Nutra Pharma Corp.
Nutra Pharma Corp. is a biopharmaceutical company specializing in the
acquisition, licensing and commercialization of pharmaceutical products
and technologies for the management of neurological disorders, cancer,
autoimmune and infectious diseases. Nutra Pharma Corp. through its
subsidiaries carries out basic drug discovery research and clinical
development and also seeks strategic licensing partnerships to reduce
the risks associated with the drug development process. The Company's
holding, ReceptoPharm, Inc, is developing technologies for the
production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's
subsidiary, Designer Diagnostics is engaged in the research and
development of diagnostic test kits designed to be used for the rapid
identification of infectious diseases such as Tuberculosis (TB) and
Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to
identify and acquire intellectual property and companies in the
biotechnology arena.
This press release contains forward-looking statements. The words or
phrases "would be," "will allow," "intends to," "will likely result,"
"are expected to," "will continue," "is anticipated," "estimate,"
"project," or similar expressions are intended to identify
"forward-looking statements." Actual results could differ materially
from those projected in Nutra Pharma's ("the Company") business plan.
The Company's business is subject to various risks, which are discussed
in the Company's filings with the Securities and Exchange Commission
("SEC").The results from the microarray studies should
not be construed as an indication in any way whatsoever of the value of
the Company or its common stock.The Company's filings may be
accessed at the SEC's Edgar system at www.sec.gov.Statements made herein are as of the date of this press release and
should not be relied upon as of any subsequent date. The Company
cautions readers not to place reliance on such statements. Unless
otherwise required by applicable law, we do not undertake, and we
specifically disclaim any obligation, to update any forward-looking
statements to reflect occurrences, developments, unanticipated events or
circumstances after the date of such statement.
